Nuvation Bio 2024 Investor Presentation

Nuvation Bio presents its oncology-focused pipeline of wholly-owned drug candidates, including NUV-868 (BET inhibitor) and NUV-1511 (drug-drug conjugate), currently in Phase 1/1b and preclinical development. The January 2024 presentation outlines clinical trial progress in advanced solid tumors, metastatic breast cancer, and prostate cancer, with plans to initiate Phase 1/2 studies for NUV-1511 in the first half of 2024.